Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Data for anzutresgene autoleucel presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago support a future…
Blog - Melanoma360
06/05/2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Data for anzutresgene autoleucel presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago support a future…
|
06/05/2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Early data for imneskibart with aldesleukin presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago support…
|
06/05/2026
Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)
Data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago show that an mRNA individualized neoantigen…
|
06/03/2026
Why Are Young People Tanning Again? What a New Allure Feature Reveals About Melanoma Prevention Challenges
A recent feature in Allure magazine explores a concerning trend: The resurgence of tanning culture among younger generations. The article…
05/29/2026
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies,…
|
05/26/2026
The Importance of Self-Advocacy
by Mara Klecker Donna Altes was in her late 70s when she received her melanoma diagnosis, which came after a…
|
05/21/2026
Webinar: Post-ASCO Melanoma Research Update
Each year, the American Society of Clinical Oncology (ASCO) Annual Meeting brings together leading cancer researchers and physicians from around…
|
05/04/2026
Melanoma Monday: Every Day. Everywhere.
May is Melanoma Awareness Month—but melanoma doesn’t follow a calendar. It doesn’t wait for summer vacations or long afternoons at…
04/27/2026
Lilly Pulitzer and AIM at Melanoma Partner for 5th Annual Community Giving Event
AIM at Melanoma is proud to partner once again with Lilly Pulitzer for their annual Community Giving Event. Now in…
|
04/19/2026
KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma
OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as…
|
|
Recent Posts
Jul. 20, 2026
More Than a Letter: A Year of Advocacy for Patients with Advanced Melanoma
Jul. 14, 2026
Finding Hope, Purpose, and Life Beyond Diagnosis
Jul. 10, 2026
Help Bring a New Treatment Option to Patients with Advanced Melanoma
Jul. 06, 2026
How Melanoma Changed Adam Harper’s Perspective on Life
Jun. 26, 2026